REFERENCES
1. Germeshausen M, Ballmaier M. Congenital amegakaryocytic thrombocytopenia - not a single disease. Best Pract Res Clin Haematol. 2021;34:101286.
3. Dobrewa W, Bielska M, Bąbol-Pokora K, Janczar S, Młynarski W. Congenital neutropenia: from lab bench to clinic bedside and back. Mutat Res Rev Mutat Res. 2024;793:108476.
4. Revy P, Kannengiesser C, Bertuch AA. Genetics of human telomere biology disorders. Nat Rev Genet. 2023;24:86-108.
5. Tummala H, Walne AJ, Badat M, et al. The evolving genetic landscape of telomere biology disorder dyskeratosis congenita. EMBO Mol Med. 2024;16:2560-82.
6. Boussion S, Escande F, Jourdain AS, et al. TAR syndrome: clinical and molecular characterization of a cohort of 26 patients and description of novel noncoding variants of RBM8A. Hum Mutat. 2020;41:1220-5.
7. Da Costa L, Mohandas N, David-NGuyen L, et al. Diamond-blackfan anemia, the archetype of ribosomopathy: how distinct is it from the other constitutional ribosomopathies? Blood Cells Mol Dis. 2024;106:102838.
8. Kawashima N, Oyarbide U, Cipolli M, Bezzerri V, Corey SJ. Shwachman-Diamond syndromes: clinical, genetic, and biochemical insights from the rare variants. Haematologica. 2023;108:2594-605.
9. Bhandari J, Thada PK, Killeen RB, Puckett Y. Fanconi anemia. Treasure Island: StatPearls Publishing; 2024.
11. Lee JM, Kim HS, Yoo J, et al. Genomic insights into inherited bone marrow failure syndromes in a Korean population. Br J Haematol. 2024;205:1581-9.
12. Gutierrez-Rodrigues F, Patel BA, Groarke EM. When to consider inherited marrow failure syndromes in adults. Hematol Am Soc Hematol Educ Program. 2023;2023:548-55.
13. Fox LC, McQuilten ZK, Firkin F, et al. The Australian aplastic Anaemia and other bone marrow failure syndromes registry. Best Pract Res Clin Haematol. 2023;36:101516.
14. Leal-Anaya P, Kimball TN, Yanez-Felix AL, et al. Inherited bone marrow failure syndromes: phenotype as a tool for early diagnostic suspicion at a major reference center in Mexico. Front Genet. 2023;14:1293929.
16. Deng J, McReynolds LJ. Inherited bone marrow failure syndromes: a review of current practices and potential future research directions. Curr Opin Pediatr. 2023;35:75-83.
17. Groarke EM, Calado RT, Liu JM. Cell senescence and malignant transformation in the inherited bone marrow failure syndromes: overlapping pathophysiology with therapeutic implications. Semin Hematol. 2022;59:30-7.
18. Lipton JM, Molmenti CLS, Desai P, Lipton A, Ellis SR, Vlachos A. Early onset colorectal cancer: an emerging cancer risk in patients with diamond Blackfan anemia. Genes. 2021;13:56.
19. Schratz KE, Haley L, Danoff SK, et al. Cancer spectrum and outcomes in the Mendelian short telomere syndromes. Blood. 2020;135:1946-56.
20. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the national cancer institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica. 2018;103:30-9.
21. Keel SB, Scott A, Sanchez-Bonilla M, et al. Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. Haematologica. 2016;101:1343-50.
22. Gálvez E, Vallespín E, Arias-Salgado EG, et al. Next-generation sequencing in bone marrow failure syndromes and isolated cytopenias: experience of the spanish network on bone marrow failure syndromes. Hemasphere. 2021;5:e539.
23. Ghemlas I, Li H, Zlateska B, et al. Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes. J Med Genet. 2015;52:575-84.
24. Zhang MY, Keel SB, Walsh T, et al. Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. Haematologica. 2015;100:42-8.
25. Muramatsu H, Okuno Y, Yoshida K, et al. Clinical utility of next-generation sequencing for inherited bone marrow failure syndromes. Genet Med. 2017;19:796-802.
26. Bluteau O, Sebert M, Leblanc T, et al. A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. Blood. 2018;131:717-32.
27. Blombery P, Fox L, Ryland GL, et al. Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes. Haematologica. 2021;106:64-73.
28. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17:333-51.
29. Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: a British society for haematology guideline. Br J Haematol. 2024;204:784-804.
30. Shimano KA, Narla A, Rose MJ, et al. Diagnostic work-up for severe aplastic anemia in children: consensus of the North American pediatric aplastic anemia consortium. Am J Hematol. 2021;96:1491-504.
31. Roy NBA, Da Costa L, Russo R, et al. The use of next-generation sequencing in the diagnosis of rare inherited anaemias: a joint BSH/EHA good practice paper. Hemasphere. 2022;6:e739.
32. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703-19.
33. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345-77.
34. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-28.
35. Greenberg PL, Stone RM, Al-Kali A, et al. NCCN guidelines® insights: myelodysplastic syndromes, version 3.2022. J Natl Compr Canc Netw. 2022;20:106-17.
36. Feurstein S, Hahn CN, Mehta N, Godley LA. A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias. Genet Med. 2022;24:931-54.
37. Gutierrez-Rodrigues F, Sahoo SS, Wlodarski MW, Young NS. Somatic mosaicism in inherited bone marrow failure syndromes. Best Pract Res Clin Haematol. 2021;34:101279.
38. Schratz KE, Gaysinskaya V, Cosner ZL, et al. Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders. J Clin Invest. 2021;131:e147598.
39. Trottier AM, Godley LA. Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities. Br J Haematol. 2021;194:663-76.
40. McReynolds LJ, Rafati M, Wang Y, et al. Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes. Blood. 2022;140:909-21.
41. Agarwal S. Minimal intensity conditioning strategies for bone marrow failure: is it time for "preventative" transplants? Hematol Am Soc Hematol Educ Program. 2023;2023:135-40.
42. Alter BP. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Hematol Am Soc Hematol Educ Program. 2017;2017:88-95.
43. Atmar K, Ruivenkamp CAL, Hooimeijer L, et al. Diagnostic value of a protocolized in-depth evaluation of pediatric bone marrow failure: a multi-center prospective cohort study. Front Immunol. 2022;13:883826.
44. Bonfim C. Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes. Hematol Am Soc Hematol Educ Program. 2020;2020:107-14.
45. Dietz AC, Mehta PA, Vlachos A, et al. Current knowledge and priorities for future research in late effects after hematopoietic cell transplantation for inherited bone marrow failure syndromes: consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23:726-35.
46. Dietz AC, Savage SA, Vlachos A, et al. Late effects screening guidelines after hematopoietic cell transplantation for inherited bone marrow failure syndromes: consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT. Biol Blood Marrow Transplant. 2017;23:1422-8.
47. Hudda Z, Myers KC. Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes? Hematol Am Soc Hematol Educ Program. 2023;2023:141-8.
48. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24.
49. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020;22:245-57.
50. Alder JK, Hanumanthu VS, Strong MA, et al. Diagnostic utility of telomere length testing in a hospital-based setting. Proc Natl Acad Sci USA. 2018;115:E2358-65.
51. Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23:2029-37.
52. Godley LA, DiNardo CD, Bolton K. Germline predisposition in hematologic malignancies: testing, management, and implications. Am Soc Clin Oncol Educ Book. 2024;44:e432218.
53. Padron E, Ball MC, Teer JK, et al. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood. 2018;131:2402-5.
54. Ceyhan-Birsoy O, Fiala E, Rana S, et al. Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings. Haematologica. 2024;109:3383-90.
55. Stewart BL, Helber H, Bannon SA, et al. Risk assessment and genetic counseling for hematologic malignancies-Practice resource of the National Society of Genetic Counselors. J Genet Couns. 2025;34:e1959.
56. Ma K, Huang S, Ng KK, et al. Saturation mutagenesis-reinforced functional assays for disease-related genes. Cell. 2024;187:6707-24.e22.
57. Sanchez SE, Gu Y, Wang Y, et al. Digital telomere measurement by long-read sequencing distinguishes healthy aging from disease. Nat Commun. 2024;15:5148.
58. Tham CY, Poon L, Yan T, et al. High-throughput telomere length measurement at nucleotide resolution using the PacBio high fidelity sequencing platform. Nat Commun. 2023;14:281.
59. Sholes SL, Karimian K, Gershman A, Kelly TJ, Timp W, Greider CW. Chromosome-specific telomere lengths and the minimal functional telomere revealed by nanopore sequencing. Genome Res. 2022;32:616-28.
60. Smirnov D, Konstantinovskiy N, Prokisch H. Integrative omics approaches to advance rare disease diagnostics. J Inherit Metab Dis. 2023;46:824-38.
61. Marwaha S, Knowles JW, Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. 2022;14:23.
62. Montgomery SB, Bernstein JA, Wheeler MT. Toward transcriptomics as a primary tool for rare disease investigation. Cold Spring Harb Mol Case Stud. 2022;8:a006198.
63. Cummings BB, Marshall JL, Tukiainen T, et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci Transl Med. 2017;9:eaal5209.
64. Zech M, Dzinovic I, Skorvanek M, et al. Combined genomics and proteomics unveils elusive variants and vast aetiologic heterogeneity in dystonia. Brain. 2025:awaf059.
65. Musunuru K, Bernstein D, Cole FS, et al. Functional assays to screen and dissect genomic hits: doubling down on the national investment in genomic research. Circ Genom Precis Med. 2018;11:e002178.
66. Olijnik AA, Rodriguez-Romera A, Wong ZC, et al. Generating human bone marrow organoids for disease modeling and drug discovery. Nat Protoc. 2024;19:2117-46.
